Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison

WX Qi, L Tang, A He, Z Shen, F Lin… - … Medical Research and …, 2012 - Taylor & Francis
Background: Two new agents have recently been licensed as maintenance therapy for
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …
被引用次数：14 相关文章

Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.

WX Qi, LN Tang, AN He, Z Shen, F Lin… - … Medical Research and …, 2012 - europepmc.org
Background Two new agents have recently been licensed as maintenance therapy for
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …

Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison

WX Qi, L Tang, A He, Z Shen… - … medical research and …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Two new agents have recently been licensed as maintenance therapy for
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …
[HTML] nih.gov

[HTML][HTML] Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison

WX Qi, LN Tang, AN He, Z Shen, F Lin… - Database of Abstracts of …, 2012 - ncbi.nlm.nih.gov
The review concluded that maintenance treatment with erlotinib or pemetrexed had clinical
advantages over treatment with placebo or observation in patients with advanced non-small …